Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis
Status:
Withdrawn
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the therapeutic effectiveness of combination
antifungal therapy (CAT) of voriconazole plus micafungin versus voriconazole plus placebo
equivalent as primary therapy for invasive aspergillosis (IA) in patients with hematological
cancer.